|
||
| |||||||
|
Introduction: The goal of hormone replacement therapy (HRT) has long been to relieve menopausal symptoms and prevent chronic postmenopausal conditions, such as osteoporosis and cardiovascular disease (CVD). The halt of the estrogen/progestin arm of the Women's Health Initiative study, which revealed increased risks of breast cancer and CVD, has precipitated a shift in the perception and prescription of HRT. Scope: * Evaluation of menopause prevalence and HRT use in the seven major pharmaceutical markets: the US, Japan, France, Germany, Italy, Spain and the UK * Interviews with 107 gynecologists and primary care physicians across the seven major pharmaceutical markets in October 2002 * Assessment of the WHI study findings and the level of awareness among the physician and patient communities * Discussion of the impact of the WHI study on HRT prescribing, with specific focus on the US market and Prempro Report Highlights: Since the WHI study, Wyeth experienced a decline in share price and sales of Premarin brand products. The company should extend investment already underway for low-dose Prempro/Premarin products to remain competitive in the HRT market. The WHI has forced the HRT sector to refocus on the core indications of menopausal symptoms. Datamonitor believes that there may now be an opportunity for other pharmaceutical companies with HRT, osteoporosis, and CVD products to increase their menopausal and postmenopausal market share. Datamonitor primary research indicates that over the next 12 months the use of HRT in osteoporosis and CVD will decline. Duration of therapy will be limited to five years and the most significant effects will be seen in the US. Reasons to Purchase: * Understand the impact of the termination of the WHI study on the use of HRT * Track the direct effect of the WHI on Prempro the use by US physicians * Plan product development and marketing strategies, based on expected trends in the HRT market Publisher: Datamonitor Womens Health Reports To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Womens_Health.html#a384 |
|
|
